MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eimce.2025.03.017

Медицинская библиотека · Enfermedades infecciosas y microbiologia clinica (English ed.) · 2025

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department.

Silva-Afonso Raíssa de Fátima, Platas-Abenza Guillermo, Guerrero-Soler María, Gallardo-Rodríguez Pilar, Gil-Sánchez Francisco, Pérez-Paz Gonzalo, Cartagena-Llopis Lidia, Fuster-Pérez Marina, Sánchez-Valero María, Esclapez-Martínez Ana, Solís-Aniorte Noemí, Fernández-Martínez Yamilet, Ronda-Pérez Elena, Escribano-Cañadas Isabel, Rodríguez-Díaz Juan Carlos, Merino De Lucas Esperanza, Chico-Sánchez Pablo, Sánchez-Payá José, Gras-Valentí Paula

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

A public funded immunization program targeting influenza, COVID-19 and respiratory syncytial virus (RSV), was introduced in Spain for the 2023/2024 season. Effective immunization strategies depend on product coverage and effectiveness.

OBJECTIVES

Estimate of the impact of three severe acute respiratory infections (SARI) immunization strategies, during the 2023/2024 respiratory illness season in a Spanish health department.

METHODS

We conducted an ecological study to compare cumulative hospitalization rates of SARI between the 2022/2023 and 2023/2024 seasons. Subsequently, a cross-sectional study was conducted to describe immunization coverage. Three observational test-negative case-control studies were carried out to evaluate the vaccine effectiveness (VE) against influenza and COVID-19 and the effectiveness of immunization with nirsevimab.

RESULTS

During the 2023/2024 season 2952 patients were hospitalized due to SARI, representing hospitalization rates of 322.6/100,000 inhabitants (RR=0.78), indicating a 21.8% (CI: 14.8-28.1) overall effectiveness of the immunization strategies (EIS) against SARI. The global EIS for influenza was 26.7% (CI: 15.2-36.7), with 5.9% (CI: -10.1-19.5) for influenza A and 94.0% (CI: 86.4-97.4) for influenza B. For COVID-19, the EIS was 19.3% (CI: 7.2-29.3). The EIS for RSV was 52.5% (CI: 35.4-65.0) in children <1 year-old. For the 2023/2024 season, influenza vaccination in those aged >64 decreased 7.9%, while COVID-19 vaccination fell by 40.6% in individuals >60 years. Nirsevimab reached high coverage of 94.78%. The aVE was 28.2% (CI: 4.7-45.9) for influenza and 29.2% (CI: 7.1-46.0) for COVID-19. The overall adjusted effectiveness of nirsevimab was 63.8% (CI: 9.6-85.5).

CONCLUSION

The observed EIS was likely due to RSV immunization in infants' high coverage with good effectiveness and low influenza B circulation.

Для цитирования: Silva-Afonso Raíssa de Fátima, Platas-Abenza Guillermo, Guerrero-Soler María, Gallardo-Rodríguez Pilar, Gil-Sánchez Francisco, Pérez-Paz Gonzalo, Cartagena-Llopis Lidia, Fuster-Pérez Marina, Sánchez-Valero María, Esclapez-Martínez Ana, Solís-Aniorte Noemí, Fernández-Martínez Yamilet, Ronda-Pérez Elena, Escribano-Cañadas Isabel, Rodríguez-Díaz Juan Carlos, Merino De Lucas Esperanza, Chico-Sánchez Pablo, Sánchez-Payá José, Gras-Valentí Paula. Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department.. Enfermedades infecciosas y microbiologia clinica (English ed.). 2025. DOI: 10.1016/j.eimce.2025.03.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.